| 2026-06-12 17:22 |
8-K |
["7.01", "8.01"] |
merger agreement |
0.98
|
Definitive merger agreement with Ligand Pharmaceuticals; closing expected July 14, 2026; proxy filed. |
SEC · detail |
| 2026-06-10 17:19 |
DEFM14A |
|
merger agreement |
0.98
|
Definitive merger agreement: Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share cash plus CVRs. |
SEC · detail |
| 2026-05-22 06:01 |
8-K |
["5.02", "5.03", "5.07", "9.01"] |
merger agreement |
0.92
|
8-K discloses merger agreement with Ligand Pharmaceuticals; bylaw amendments adopted in connection with merger transaction. |
SEC · detail |
| 2026-05-18 09:11 |
8-K |
["1.01"] |
merger agreement |
0.98
|
XOMA Royalty entered into definitive merger agreement with Ligand Pharmaceuticals; Amendment No. 1 filed May 16, 2026. |
SEC · detail |
| 2026-04-27 16:01 |
8-K |
["2.01"] |
tender offer |
0.98
|
XOMA Royalty completed acquisition of Generation Bio via tender offer and merger on Feb 9, 2026. |
SEC · detail |
| 2026-04-27 08:16 |
8-K |
["1.01"] |
merger agreement |
0.98
|
Definitive merger agreement: Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share cash plus CVR. |
SEC · detail |